Načítá se...
Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status
The retrospective study was conducted to evaluate the efficacy and safety of careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer (aGC) patients with poor performance status (PS = 2 or 3). Patients with aGC of poor PS who had received at least 2 lines o...
Uloženo v:
| Vydáno v: | Medicine (Baltimore) |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Health
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6855580/ https://ncbi.nlm.nih.gov/pubmed/31702665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000017890 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|